A Phase I/III, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies

被引：2

作者：

Jurczak, Wojciech ^{[1
]}

Rule, Simon ^{[2
]}

Townsend, William ^{[3
]}

Tucker, David ^{[4
]}

Sarholz, Barbara ^{[5
]}

Scheele, Jurgen ^{[6
]}

Gribben, John G. ^{[7
]}

Zinzani, Pier Luigi ^{[8
]}

机构：

[1] Jagiellonian Univ, Dept Haematol, Krakow, Poland

[2] Plymouth Univ, Dept Haematol, Sch Med, Plymouth, Devon, England

[3] Univ Coll London Hosp NHS Fdn Trust, NIHR UCLH Clin Res Facil, London, England

[4] Torbay Hosp, Dept Haematol, Torquay, England

[5] Merck KGaA, R&D Global Biostat & Epidemiol, Darmstadt, Germany

[6] Merck KGaA, Global Clin Dev, Darmstadt, Germany

[7] Queen Mary Univ London, Ctr Haematooncol, Barts Canc Inst, London, England

[8] Ist Ematol, Bologna, Italy

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-112808

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4161

引用

页数：2

共 50 条

[41] Development of REDX05194, a Novel, Potent and Selective Inhibitor of Bruton's Tyrosine Kinase (BTK) As a Potential Treatment for B-Cell Malignancies
Walker, Victoria
Guisot, Nicolas E. S.
Best, Stuart
Talab, Fatima
Lucas, Catherine L.
Refuerzo, Julienne
Calder, Mathew
Proctor, Lauren
Muller, Melanie
Ho, Kelvin
Chappell, Rose
Emmerich, Juliette
Harmon, Shona
Bingham, Matilda
Campbell, Mary-Ann
Armer, Richard
BLOOD, 2015, 126 (23)
[42] Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies
Searle, Emma
Forconi, Francesco
Linton, Kim
Danilov, Alexey
Mckay, Pam
Lewis, David
El-Sharkawi, Dima
Gleeson, Mary
Riches, John
Injac, Sarah G.
Shih, Ted
Nandakumar, Srinand
Tan, May
Cherala, Ganesh
Meredith, Erin
Collins, Graham P.
BLOOD, 2023, 142
[43] An essential role for tyrosine kinase in the regulation of Bruton's B-cell apoptosis
Anderson, JS
Teutsch, M
Dong, ZJ
Wortis, HH
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (20) : 10966 - 10971
[44] An essential role for tyrosine kinase in the regulation of Bruton's B-cell apoptosis
Proc Natl Acad Sci USA, 26 (15522):
[45] Bruton's tyrosine kinase is essential for human B cell tolerance
Ng, YS
Wardemann, H
Chelnis, J
Cunningham-Rundles, C
Meffre, E
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (07): : 927 - 934
[46] How We Manage Patients with Indolent B-Cell Malignancies on Bruton's Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists
Nixon, Shannon
Duquette, Dominic
Doucette, Sarah
Larouche, Jean-Francois
CURRENT ONCOLOGY, 2023, 30 (04) : 4222 - 4245
[47] Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies
Ponader, Sabine
Burger, Jan A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (17) : 1830 - U115
[48] Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B-Cell Malignancies
Demin, Oleg
Ou, Ying
Kolesova, Galina
Shchelokov, Dmitry
Stepanov, Alexander
Musatova, Veronika
Sahasranaman, Sri
Zhao, Yating
Liu, Xiangyu
Tang, Zhiyu
Hanley, William D.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2025,
[49] The Selective Bruton Tyrosine Kinase Inhibitor TG-1701 as Monotherapy and in Combination With Ublituximab and Umbralisib (U2) in Patients With B-Cell Malignancies
Coombs, Catherine Callaghan
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 11 - 12
[50] The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective
Satterthwaite, AB
Witte, ON
IMMUNOLOGICAL REVIEWS, 2000, 175 : 120 - 127

← 1 2 3 4 5 →